Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820285 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL23485195 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL15589451 | 0.91 | FKBP1A (0.49) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL30963600 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL7659903 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL8728752 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL821085 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL30963525 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL818418 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL21874110 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2242362-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | SMN1; SMN2 1875/4885NPC1 2535/4885RAB9A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.